Drug Profile
Teclistamab - Genmab/Janssen Research & Development
Alternative Names: BCMAxCD3 - Genmab/Janssen Research & Development; JNJ 7957; JNJ-64007957; teclistamab-cqyv; TECVAYLILatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Genmab; Janssen Research & Development
- Developer Janssen Research & Development
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple myeloma
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in Japan (SC, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Israel (SC, Injection)
- 09 Dec 2023 Efficacy and safety data from a phase II trial in Multiple myeloma released by Janssen Pharmaceutical